Hypocellular Marrow Causes and Diagnostic Considerations

Primary Hematologic Causes

The American Society of Hematology recommends that idiopathic aplastic anemia be characterized by severely reduced cellularity (<20% in severe cases, age-corrected) with blast percentage below 1% 1, 2
Bone marrow in aplastic anemia shows fatty replacement of normal hematopoietic tissue without dysplasia or abnormal blast clusters 3, 2
Hypocellular myelodysplastic syndromes (H-MDS) represent 7-29% of MDS cases and present with hypocellular marrow but with unequivocal dysplasia distinguishing it from aplastic anemia 4, 5
H-MDS features moderate to severe erythroid dysplasia, abnormal sideroblasts, and blast percentage of 5% or higher (in absence of significant dysplasia) 2
The risk of progression to acute leukemia is much greater in H-MDS than aplastic anemia, making accurate diagnosis essential for treatment planning 4, 5
Hypocellular acute myeloid leukemia (H-AML) is defined by ≥20% blasts on aspirate in a hypocellular setting, though this can be challenging to identify in inadequate aspirates 7, 4
The presence of clusters of immature precursors (ALIP) in biopsy with absence of sufficient numbers of granulocytes establishes H-AML diagnosis 7, 2
H-AML represents 2.2% of AML cases when age-corrected 4, 5

Chemotherapy exposure, particularly alkylating agents and purine analogues, causes secondary hypocellular marrow 6
Benzene and its derivatives from occupational exposure can cause hypocellular marrow 6
Ionizing radiation and radiotherapy exposure can cause hypocellular marrow 6
Occupational factors in agricultural and industrial workers can cause hypocellular marrow 6
Paroxysmal nocturnal hemoglobinuria (PNH) requires screening by sensitive flow cytometry 2

Fanconi anemia is more common in pediatric cases but can present in adults 6
Down syndrome and neurofibromatosis can cause inherited bone marrow failure syndromes 6
Germline predisposition should be assessed in young adults or families with MDS, AML, or aplastic anemia 6

Age correction is mandatory when assessing bone marrow cellularity - failure to correct for age dramatically overestimates hypocellular cases (from 13% to 2.2% in AML when corrected) 4, 1, 2
Blast count accuracy requires 500-cell differential - a 100-cell count has unacceptably wide confidence intervals (95% CI: 1.6-11.3% for a 5% blast count) versus 500-cell count (95% CI: 3.3-7.3%) 7, 4
Misdiagnosis between aplastic anemia and H-MDS/H-AML leads to inappropriate treatment - aplastic anemia requires immunosuppression or transplant, while H-AML requires acute leukemia chemotherapy, and H-MDS has intermediate management 1, 2
Review by at least two observers is essential when diagnostic doubt exists, particularly for H-AML cases where concordance among experts is only 57% 7, 5